# US 2013/0158238 A1 · Compositions and Methods for the Therapy and Diagnosis of Influenza

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158238 A1
- Document ID: US20130158238A1
- Status: Published application
- Kind: A1
- Application number: 13/772,976
- Filed: 2013-02-21
- Published: 2013-06-20
- Earliest claimed: 2007-11-12
- Assignees: Theraclone Sciences, Inc.
- Inventors: Andres G. Grandea, III; Gordon King; Thomas C. Cox; Ole Olsen; Jennifer Mitcham; Matthew Moyle; Phil Hammond
- Web page: https://patentgrep.com/patent/US20130158238A1

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/005: from viruses
- G01N 33/56983: {Viruses}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.

## Claims

### Claim 1

An isolated fully human monoclonal anti-matrix 2 ectodomain (M2e) antibody comprising:
a) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 44 and a light chain sequence comprising amino acid sequence SEQ ID NO: 46;
b) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 319 and a light chain sequence comprising amino acid sequence SEQ ID NO: 46;
c) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 321 and a light chain sequence comprising amino acid sequence SEQ ID NO: 46;
d) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 50 and a light chain sequence comprising amino acid sequence SEQ ID NO: 52;
e) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 323 and a light chain sequence comprising amino acid sequence SEQ ID NO: 52; or
f) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 325 and a light chain sequence comprising amino acid sequence SEQ ID NO: 52.
